Key result
Refolded recombinant HIV-1 tat protein protected both the bulge and loop regions of TAR RNA from ribonucleolytic cleavage, demonstrating a 30-fold enhanced affinity (Kd < 25 nM).
Refolded HIV-1 tat protein demonstrates enhanced affinity and specificity for TAR RNA, protecting both bulge and loop nucleotides from ribonucleolytic cleavage.
Does not alter HIV care; leaves open tat-TAR targeting for future antiviral development.
Substantial evidence indicates that HIV-1 trans-activation by tat protein is mediated through the TAR RNA element. This RNA forms a stem-loop structure containing a three-nucleotide bulge and a six-nucleotide loop. Previous mutagenic analysis of TAR indicates that the bulge residues and a 4 bp segment of the stem constitute, in part, the tat binding site. However, there appears to be no sequence-specific contribution of the six-base loop. We have employed a ribonuclease protection technique to explore the interaction of tat with single-stranded regions of TAR. The results indicate that tat interacts with both the bulge and loop regions of TAR. Treatment of TAR RNA with RNase A results in cleavage at U23 and U31, located in the bulge and loop regions, respectively. High concentrations (approximately 2 microM) of Escherichia coli derived tat protein, prepared by standard procedures, gave complete protection of TAR RNA from RNase A cleavage. However, under these conditions, truncated TAR derivatives in which no stem-loop structure is expected to form were also protected, indicating nonspecific binding. In order to obtain a tat preparation with enhanced specificity toward TAR RNA, methods were developed for refolding the recombinant protein. This treatment enhanced the affinity of tat for TAR by approximately 30-fold [Kd(apparent) less than 25 nM] and markedly increased its specificity for the TAR. Again, tat protected TAR RNA from RNase A cleavage at both U23 and U31. Protection was also observed with RNase T1 which cleaves TAR RNA at three G residues in the six-base loop.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Harper et al. (1991) studied HIV-1. Refolded recombinant HIV-1 tat protein vs. Standard tat protein / untreated TAR RNA was evaluated on Protection of TAR RNA from ribonucleolytic cleavage. Refolded recombinant HIV-1 tat protein protected both the bulge and loop regions of TAR RNA from ribonucleolytic cleavage, demonstrating a 30-fold enhanced affinity (Kd < 25 nM).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: